Just had a quick look and it seems GSLI was treating patients that were HER2+ve and had been treated with Herceptin where as IMMP was treating HER2 -ve patients which I suspect (not a clinician) is the harder category to treat? Anyone else shed some light?
Ann: Overall Survival data from ph IIb AIPAC breast cancer trial, page-56
-
- There are more pages in this discussion • 193 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.0¢ | 34.0¢ | $1.270M | 3.611M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 286261 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 253490 | 7 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |